Stock market today: Stocks fall as investors rotate out of tech into Jackson Hole
Mirum Pharmaceuticals Inc. stock reached an all-time high of 67.5 USD, marking a significant milestone for the company. With a market capitalization of $3.38 billion, the company demonstrates strong financial health with a comfortable current ratio of 3.13. According to InvestingPro analysis, the stock appears to be trading slightly above its Fair Value. This achievement reflects a robust 64.86% increase in the stock’s value over the past year, showcasing investor confidence and strong market performance. The company’s impressive 62.33% revenue growth and innovative approaches in the pharmaceutical sector have contributed to this upward trajectory, positioning Mirum Pharmaceuticals as a noteworthy player in the industry. For deeper insights and additional ProTips about MIRM’s valuation and growth prospects, explore the comprehensive Pro Research Report available on InvestingPro.
In other recent news, Mirum Pharmaceuticals reported strong financial results for the second quarter of 2025. The company achieved total revenues of $127.8 million, marking a 64% increase compared to the same period in 2024. Earnings per share were reported at -$0.12, significantly outperforming the forecasted -$0.33. Following these results, Mirum’s management has raised its 2025 revenue guidance to a range of $490 million to $510 million, indicating a 48% year-over-year growth at the midpoint.
In light of these developments, H.C. Wainwright increased its price target for Mirum Pharmaceuticals from $73 to $80, maintaining a Buy rating. Similarly, JMP Securities raised its price target to $81 from $79, also maintaining a Market Outperform rating. Stifel has resumed coverage of Mirum Pharmaceuticals with a Buy rating and set a price target of $89. The firm emphasized the company’s cash-flow positive status and its promising pipeline, including an upcoming pivotal catalyst expected in 2026.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.